Testing effectiveness (Phase 2)Study completedNCT03352947
What this trial is testing
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
Who this might be right for
Melanoma
Cambridge University Hospitals NHS Foundation Trust 79